8.60
-0.03
(-0.41%)
At close: April 16 at 4:00:01 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.09 | -0.05 | 0.26 | -0.32 |
| Low Estimate | -0.1 | -0.08 | 0.23 | -0.35 |
| High Estimate | -0.08 | -0.01 | 0.3 | -0.29 |
| Year Ago EPS | -0.09 | -0.13 | -0.33 | 0.26 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 28.07M | 16.1M | 103.26M | 86.7M |
| Low Estimate | 14.5M | 15M | 93M | 70.4M |
| High Estimate | 65.8M | 17.1M | 126.9M | 107.7M |
| Year Ago Sales | 14.5M | 14.26M | 64.38M | 103.26M |
| Sales Growth (year/est) | 93.58% | 12.93% | 60.39% | -16.03% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.12 | -0.07 | -0.1 | -0.08 |
| EPS Actual | -0.09 | -0.13 | -0.06 | -0.05 |
| Difference | 0.03 | -0.06 | 0.04 | 0.03 |
| Surprise % | 21.58% | -85.71% | 42.90% | 39.88% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.05 | 0.26 | -0.32 |
| 7 Days Ago | -0.09 | -0.05 | 0.26 | -0.32 |
| 30 Days Ago | -0.09 | -0.05 | 0.26 | -0.32 |
| 60 Days Ago | -0.06 | -0.05 | 0.96 | 1.03 |
| 90 Days Ago | -0.06 | -0.05 | 0.96 | 1.03 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | 2 | 2 |
| Down Last 30 Days | -- | -- | 2 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TBPH | 4.36% | 65.38% | 180.08% | -220.75% |
| S&P 500 | 6.79% | 5.59% | 9.06% | 14.11% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/27/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/25/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/6/2024 |
| Maintains | TD Cowen: Hold to Hold | 8/6/2024 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 8/6/2024 |
Related Tickers
HLVX HilleVax, Inc.
1.6500
0.00%
IPSC Century Therapeutics, Inc.
0.5000
-0.20%
ASMB Assembly Biosciences, Inc.
10.01
+1.99%
SPRO Spero Therapeutics, Inc.
0.7400
-0.59%
BOLT Bolt Biotherapeutics, Inc.
0.3320
-3.77%
IKNA Ikena Oncology, Inc.
1.1100
-2.63%
GLTO Galecto, Inc.
2.3800
-7.39%
EPIX ESSA Pharma Inc.
1.7700
+8.59%
LVTX LAVA Therapeutics N.V.
1.2300
+7.89%
KZR Kezar Life Sciences, Inc.
4.0600
-1.22%